ADVENT Respiratory
ADVENT is a medical education programme designed to disseminate knowledge about the role of type 2 inflammation in respiratory diseases
ADVENT is developed in collaboration with an expert steering committee and links the latest science of type 2 inflammation with the clinical management of patients with type 2 diseases, such as asthma and chronic rhinosinusitis with nasal polyps.
ADVENT respiratory steering committee
Prof Phil Bardin
Professor of Respiratory Medicine in the Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne. Director, Lung Sleep Allergy & Immunology, Monash University and Medical Centre, Melbourne.
A/Prof Joy Lee
Lead of the Asthma and Allergy Unit at the Austin Hospital and consultant at Alfred Hospital Asthma, Allergy and Immunology Department and the Allergy unit at Monash Medical Centre.
Prof Peter Wark
Director of Cystic Fibrosis Service Professor of Medicine Monash University AIRMED, Alfred Health
Prof Mark Hew
Head of Allergy, Asthma & Clinical Immunology, AIRMED, Alfred Hospital. Prof at Monash University and at Melbourne Academic Centre, University of Melbourne.
Prof Connie Katelaris
Head of Unit, Immunology and Allergy Campbelltown Hospital and Professor of Immunology & Allergy, Western Sydney University.
View the Interactive Clinical Tutorial series for 2023
Biomarkers to manage severe asthma in clinical practice
View three on-demand videos that provide insights and practical tips from Profs Ian Pavord and Peter Wark on the use of biomarkers in patients with severe asthma to guide therapeutic decision-making. Also available are downloadable PDF Slides and a full reference list for the tutorial.
Remission or 'super responders' in severe asthma: same or different?
Specialists in rheumatology, oncology and immunology share their experience of remission and super responders. Discussion between the panel and audience then explores these concepts in severe asthma.
Remission or 'super responders' in severe asthma: what to target and when to switch?
Building on discussion around remission and super responder, experts discuss what to target and when to switch biologic therapy in patients with severe asthma
Watch the 2020–2022 ADVENT and ASPIRE series developed and endorsed by Australian and international experts
At ADVENTprogram.com you can:
-
Access medical education resources
- Review the latest science for Type 2 inflammatory diseases
- Explore your specific interests – select materials by category or topic
Access to ADVENTprogram.com is restricted to healthcare professionals. Registration is required to view content.
Dupixent (dupilumab) PBS Information: Authority Required.
Refer to PBS schedule for full authority information. Authority required for patients aged ≥12 years with: chronic severe atopic dermatitis: OR uncontrolled severe asthma. This product is not listed on the PBS for: children 6 months to 11 years of age with severe atopic dermatitis; children 6-11 years of age with moderate to severe asthma; adults with uncontrolled chronic rhinosinusitis with nasal polyps; or adults with moderate-to-severe prurigo nodularis.
Please review full product Information before prescribing Dupixent (dupilumab). Full Product Information is available from Sanofi-aventis Australia pty ltd here or by contacting 1800 818 806.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems
MAT-AU-2302085 - 2.0 - 11/2024